Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Melissa Bersanelli, Sebastiano Buti & Mimma Rizzo. (2021) The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 21:4, pages 401-412.
Read now
Read now
Rana Maroun, Laetitia Fleury, Gaelle Nachbaur, Franck Maunoury, Jean-louis Vanhille & Isabelle Durand-Zaleski. (2017) Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database. Current Medical Research and Opinion 33:10, pages 1755-1762.
Read now
Read now
James Larkin, Abby Paine, Grace Foley, Stephen Mitchell & Connie Chen. (2015) First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis. Expert Opinion on Pharmacotherapy 16:13, pages 1915-1927.
Read now
Read now
James E. Signorovitch, Nicholas J. Vogelzang, Sumanta K. Pal, Peggy L. Lin, Daniel J. George, Michael K. Wong, Zhimei Liu, Xufang Wang, Ken Culver, Jeffrey A. Scott & Eric Jonasch. (2014) Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Current Medical Research and Opinion 30:11, pages 2343-2353.
Read now
Read now
Hideyuki Akaza & Tomofusa Fukuyama. (2014)
Axitinib for the treatment of advanced renal cell carcinoma. Expert Opinion on Pharmacotherapy 15:2, pages 283-297.
Read now
Read now
Articles from other publishers (15)
Philippe Tuppin, Michel Paita, Christelle Gastaldi-Menager, Christine Le Bihan-Benjamin, Philippe Jean Bousquet & Anne Fagot Campagna. (2019) Patient characteristics and treatments one year after diagnosis of renal cancer in 2015 according to the presence or absence of metastasis and a history of another tumour: A national observational study. Bulletin du Cancer 106:6, pages 538-549.
Crossref
Crossref
Charlotta Karner, Kayleigh Kew, Victoria Wakefield, Natalie Masento & Steven J Edwards. (2019) Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis. BMJ Open 9:3, pages e024691.
Crossref
Crossref
Ning Shao, Hong-Kai Wang, Yao Zhu & Ding-Wei Ye. (2018) Modification of American Joint Committee on cancer prognostic groups for renal cell carcinoma. Cancer Medicine 7:11, pages 5431-5438.
Crossref
Crossref
Chao Wei, Shen Wang, Zhangqun Ye & Zhiqiang Chen. (2018) Efficacy of targeted therapy for advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials. International braz j urol 44:2, pages 219-237.
Crossref
Crossref
Dinesh Kumar Chellappan, Jestin Chellian, Zhao Yin Ng, Yan Jinn Sim, Chiu Wei Theng, Joyce Ling, Mei Wong, Jia Hui Foo, Goh Jun Yang, Li Yu Hang, Saranyah Nathan, Yogendra Singh & Gaurav Gupta. (2017) The role of pazopanib on tumour angiogenesis and in the management of cancers: A review. Biomedicine & Pharmacotherapy 96, pages 768-781.
Crossref
Crossref
B.C. WuE.D. PatelA.G. Ortega-Loayza. (2017) Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. British Journal of Dermatology 177:1, pages 72-83.
Crossref
Crossref
Rana Maroun, Franck Maunoury, Laure Benjamin, Gaëlle Nachbaur & Isabelle Durand-Zaleski. (2016) In-Hospital Economic Burden of Metastatic Renal Cell Carcinoma in France in the Era of Targeted Therapies: Analysis of the French National Hospital Database from 2008 to 2013. PLOS ONE 11:9, pages e0162864.
Crossref
Crossref
Kazuhiro Yamamoto, Kazuaki Shinomiya, Takeshi Ioroi, Sachi Hirata, Kenichi Harada, Manabu Suno, Tatsuya Nishioka, Manabu Kume, Hiroo Makimoto, Tsutomu Nakagawa, Takeshi Hirano, Toshinori Bito, Chikako Nishigori, Hideaki Miyake, Masato Fujisawa & Midori Hirai. (2015) Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients. Targeted Oncology 11:1, pages 93-99.
Crossref
Crossref
Mian Xie, Chao sheng He, Jin Kun Huang & Qi zhan Lin. (2015) Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: A Southern China Urology Cancer Consortium Trial. European Journal of Cancer 51:5, pages 595-603.
Crossref
Crossref
Sarah Fernandes Teixeira, Ricardo Alexandre de Azevedo, Maria Alejandra Clavijo Salomon, Salomão Dória Jorge, Débora Levy, Sérgio Paulo Bydlowski, Cecília Pessoa Rodrigues, Célia Regina Pizzo, José Alexandre Marzagão Barbuto & Adilson Kleber Ferreira. (2014) Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells. Biomedicine & Pharmacotherapy 68:8, pages 1015-1022.
Crossref
Crossref
Kazuhiro Yamamoto, Atsushi Mizumoto, Kohji Nishimura, Atsushi Uda, Akira Mukai, Kazuhiko Yamashita, Manabu Kume, Hiroo Makimoto, Toshinori Bito, Chikako Nishigori, Tsutomu Nakagawa, Takeshi Hirano & Midori Hirai. (2014) Association of Toxicity of Sorafenib and Sunitinib for Human Keratinocytes with Inhibition of Signal Transduction and Activator of Transcription 3 (STAT3). PLoS ONE 9:7, pages e102110.
Crossref
Crossref
Henry Leung, Agnes Chan & Shun‑Jen Lin. (2014) Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: A network meta‑analysis of randomised clinical trials. Molecular and Clinical Oncology.
Crossref
Crossref
V. Rohde. 2014. Facharztwissen Urologie. Facharztwissen Urologie
139
156
.
V. Rohde. 2014. Facharztwissen Urologie. Facharztwissen Urologie
139
156
.
George Dranitsaris, Susanne Schmitz & Reuben J. Broom. (2013) Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. Journal of Cancer Research and Clinical Oncology 139:11, pages 1917-1926.
Crossref
Crossref